Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Palatin Technologies Inc (NYSE MKT LLC:PTN)

During the Trading Day
0.8263 -0.0337 / -3.92%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
0.85 +0.0237 / +2.87%
Volume: 1.5K
Health Technology

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. It programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. Palatin Technologies was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Contact Information

Palatin Technologies, Inc.
Cedar Brook Corporate Center
Cranbury New Jersey 08512
P:(609) 495-2200
Investor Relations:



Other institutional32.21%
Mutual fund holders3.89%
Individual stakeholders16.89%

Top Executives

Carl SpanaPresident, Chief Executive Officer & Director
Stephen T. WillsCOO, CFO, Secretary, Treasurer & Executive VP
Johna LucasChief Medical Officer
Stephen A. SlusherChief Legal Officer